Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058589 | 0.93 | KMT2A (0.35) | MEN1KMT2ARAD52 | |
| SCHEMBL4059129 | 0.86 | KMT2A (0.38) | MEN1KMT2ARAD52 | |
| SCHEMBL4054774 | 0.82 | GRIN2D (0.30) | — | |
| SCHEMBL26272370 | 0.80 | MEN1 (0.36) | KDM1ATSHRMEN1KMT2AMAPT | |
| SCHEMBL4056212 | 0.79 | GRIN2D (0.35) | MEN1KMT2ARAD52 | |
| SCHEMBL4056020 | 0.75 | — | — | |
| SCHEMBL4065190 | 0.73 | TSHR (0.32) | TSHRMEN1KMT2AMAPTALOX15 | |
| SCHEMBL4054643 | 0.73 | MEN1 (0.47) | KDM1AMEN1KMT2ARAD52 | |
| SCHEMBL4058572 | 0.70 | — | — | |
| SCHEMBL4065177 | 0.70 | PYCR1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030248-A1 | Ethynylphenylbiadamantane derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-2014636-A1 | Ethynylphenylbiadamantane derivatives | Daicel Chemical Industries, Ltd. (JP) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030248-A1 | Ethynylphenylbiadamantane derivatives | CHRNA5, CHRNE, ADRA1D | KDM1A 2691/4885TSHR 126/4885MEN1 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.